YAP: A Turning Point for Cognitive Function in AD

Alzheimer’s Disease (AD) is a debilitating neurological condition often associated with gradual cognitive decline and memory impairment. A manner in which Alzheimer’s presents itself is by impeding the astrocytic function caused by tau aggregates and amyloid beta plaques, which are thought to play a part in the pathogenesis of AD, leading to dysregulation of neurogenesis. The brain becomes incapable of developing new neurons leading to progressive neuronal loss and cognitive deterioration typical of Alzheimer’s disease. However, recent studies have identified Yap as a promising target for new drugs. The development of many organs depends on a transcriptional cofactor known as Yes-associated protein (YAP), which is essential for the normal functioning Hippo pathway. However, its functions concerning brain development remain largely obscure. Furthermore, YAP has been seen to curb astrocytic senescence thereby enhancing neurogenesis required for combating the cognitive disorders accompanying hostile neuronal milieu common with AD. This paper examines one such study conducted wherein YAP was introduced to WT and AD mice and the results are then analyzed through rodent field tests. The results verified the claim that YAP can help curb Astrocytic Senescence and therefore retain and even slightly improve cognitive function. However, it is crucial to note that YAP has potential side effects. Side effects including tumor progression and cell proliferation are observed with YAP-inducing treatments since YAP is also a key player in organ growth and regeneration. Further study is crucial to solidify the position of YAP as a treatment for AD.